Article Text

Download PDFPDF
A Clinical Evaluation of American Brachytherapy Society Consensus Guideline for Bulky Vaginal Mass in Gynecological Cancer
  1. Keiko Nemoto Murofushi, MD*,,
  2. Nozomi Kitamura, MS*,
  3. Yasuo Yoshioka, MD, PhD*,
  4. Minako Sumi, MD, PhD*,
  5. Hitoshi Ishikawa, MD, PhD,
  6. Masahiko Oguchi, MD, PhD* and
  7. Hideyuki Sakurai, MD, PhD
  1. *Radiation Oncology Department, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo; and
  2. Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, Ibaraki, Japan.
  1. Address correspondence and reprint requests to Keiko Nemoto Murofushi, MD, Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305–8576, Japan. E-mail: murofushi{at}pmrc.tsukuba.ac.jp.

Abstract

Objectives American Brachytherapy Society (ABS)-recommended interstitial brachytherapy (IBT) should be considered for bulky vaginal tumor thicker than 5 mm. The aim of this study was to evaluate the ABS consensus guideline for patients with severe vaginal invasion based on our long-term follow-up results.

Methods/Materials The study included 7 patients with vaginal cancer and 14 patients with cervical cancer invading to the lower vagina. Based on prebrachytherapy magnetic resonance imaging findings, patients received intracavitary brachytherapy (ICT) for vaginal tumors 5 mm or less or IBT for vaginal tumors less than 5 mm. Nine patients received ICT and the remaining 12 patients received IBT. For dosimetric comparison, an experimental recalculation as the virtual IBT for patients actually treated by ICT, and vice versa, was performed.

Results The 5-year local control rate for all tumors was 89.4%. No differences in local control between ICT- and IBT-treated groups were observed (P = 0.21). One patient experienced a grade 3 rectal complication. There were no significant differences in the CTV D90 and rectum D2cc between the 2 groups (P = 0.13 and 0.39, respectively). In the dosimetric study of ICT-treated patients, neither the actual ICT plans nor the experimental IBT plans exceeded the limited dose for organs at risk, which were recommended in the guideline published from the ABS. In the IBT-treated patients, D2cc for bladder and rectum of the experimental ICT plans was significantly higher than for the actual IBT plans (P < 0.001 and <0.001, respectively), and 11 experimental ICT plans (92%) exceeded the limited dose for bladder and/or rectum D2cc.

Conclusions Tumor control and toxicity after selected brachytherapy according to vaginal tumor thickness were satisfactory; IBT instead of ICT is recommended for patients with vaginal tumor thickness greater than 5 mm to maintain bladder and/or rectum D2cc.

  • Cervical cancer with severe vaginal invasion
  • Vaginal cancer
  • Dose-volume histogram parameter
  • Image-guided brachytherapy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.